{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:17:17Z","timestamp":1788221837416,"version":"build-2803163510"},"reference-count":39,"publisher":"American Academy of Pediatrics (AAP)","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:p>Decision analytic models that project the outcomes of population-based newborn screening compared with clinical identification can inform newborn screening policymaking. A flexible decision analytic model that could be adapted for the many and growing number of conditions being considered for newborn screening would help expedite decision making while reducing the time and resources required to develop new condition-specific models. To address this need, we developed Decision Analysis to Inform Screening of the Young (DAISY), an interactive and adaptable generic newborn screening model that incorporates user-supplied inputs. To illustrate the use of this tool, we present a model of newborn screening for metachromatic leukodystrophy (MLD). DAISY projects that newborn screening would identify a greater number of MLD cases and improve survival outcomes over a 5-year time horizon compared with clinical identification. In a US birth cohort of 3.6 million newborns, we project that 36 infants with early-onset MLD cases would be identified per year through newborn screening, each of whom would be treatment eligible. In contrast, in the absence of screening, only 11.5 infants with early-onset MLD cases would be identified, 10 of whom would be treatment eligible. The number of children surviving without motor impairment approximately 5 years after symptom onset is projected to be 32.8 with newborn screening and 9.1 in the absence of screening. DAISY can be used to evaluate other newborn screening candidate conditions through specification of input parameters such as population size, clinical validity of the screening algorithm, and treatment effectiveness.<\/jats:p>","DOI":"10.1542\/peds.2026-077357g","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:03:01Z","timestamp":1788220981000},"source":"Crossref","is-referenced-by-count":0,"title":["Decision Analysis to Inform Screening of the Young: An Interactive Newborn Screening Model"],"prefix":"10.1542","volume":"158","author":[{"given":"Hadley Stevens","family":"Smith","sequence":"first","affiliation":[{"name":"1Division of Child Health Research and Policy, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts"},{"name":"2Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Stein","sequence":"additional","affiliation":[{"name":"1Division of Child Health Research and Policy, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus W.","family":"Henry","sequence":"additional","affiliation":[{"name":"1Division of Child Health Research and Policy, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy K.K.","family":"Lam","sequence":"additional","affiliation":[{"name":"3Duke Clinical and Translational Science Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margie A.","family":"Ream","sequence":"additional","affiliation":[{"name":"4Division of Child Neurology, Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelili","family":"Ojodu","sequence":"additional","affiliation":[{"name":"5Association of Public Health Laboratories, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Jones","sequence":"additional","affiliation":[{"name":"5Association of Public Health Laboratories, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Comeau","sequence":"additional","affiliation":[{"name":"6New England Newborn Screening Program, Department of Pediatrics, UMass Chan School of Medicine, Worcester, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tanksley","sequence":"additional","affiliation":[{"name":"7Texas Department of State Health Services, Public Health Laboratory Division, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Prosser","sequence":"additional","affiliation":[{"name":"8University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Kemper","sequence":"additional","affiliation":[{"name":"9Division of Primary Care Pediatrics, Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Grosse","sequence":"additional","affiliation":[{"name":"10Division of Epidemiology and Clinical Research, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"issue":"11","key":"2026083120025842700_r1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41576-023-00621-w","article-title":"Genomic newborn screening for rare diseases","volume":"24","author":"Stark","year":"2023","journal-title":"Nat Rev Genet."},{"issue":"3","key":"2026083120025842700_r2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/ijns8030040","article-title":"Newborn screening by genomic sequencing: opportunities and challenges","volume":"8","author":"Bick","year":"2022","journal-title":"Int J Neonatal Screen."},{"issue":"8","key":"2026083120025842700_r3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/gim.2012.24","article-title":"Decision analysis, economic evaluation, and newborn screening: challenges and opportunities","volume":"14","author":"Prosser","year":"2013","journal-title":"Genet Med."},{"issue":"2","key":"2026083120025842700_r4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/gim.2013.98","article-title":"Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary\u2019s Advisory Committee on Heritable Disorders in Newborns and Children","volume":"16","author":"Kemper","year":"2014","journal-title":"Genet Med."},{"issue":"1","key":"2026083120025842700_r5","doi-asserted-by":"crossref","first-page":"2381468318763814","DOI":"10.1177\/2381468318763814","article-title":"Using decision analysis to support newborn screening policy decisions: a case study for Pompe disease","volume":"3","author":"Prosser","year":"2018","journal-title":"MDM Policy Pract."},{"key":"2026083120025842700_r6","article-title":"Evidence-based review of newborn screening for spinal muscular atrophy (SMA): Final Report (v5.2)","author":"Kemper","year":"2018"},{"key":"2026083120025842700_r7","article-title":"Evidence regarding metachromatic leukodystrophy newborn screening","volume-title":"Pediatrics.","author":"Lam"},{"key":"2026083120025842700_r8","article-title":"Evidence regarding Duchenne muscular dystrophy newborn screening","volume-title":"Pediatrics.","author":"Kemper"},{"issue":"2","key":"2026083120025842700_r9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/1468-0009.12196","article-title":"The use of economic evaluation to inform newborn screening policy decisions: the Washington State experience","volume":"94","author":"Grosse","year":"2016","journal-title":"Milbank Q."},{"key":"2026083120025842700_r10","article-title":"shiny: Web Application Framework for R","author":"Chang","year":"2024"},{"issue":"4","key":"2026083120025842700_r11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/heapol\/16.4.435","article-title":"Allowing for uncertainty in economic evaluations: qualitative sensitivity analysis","volume":"16","author":"Walker","year":"2001","journal-title":"Health Policy Plan."},{"issue":"16","key":"2026083120025842700_r12","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa2405727","article-title":"Long-term effects of atidarsagene autotemcel for metachromatic leukodystrophy","volume":"392","author":"Fumagalli","year":"2025","journal-title":"N Engl J Med."},{"issue":"3","key":"2026083120025842700_r13","doi-asserted-by":"crossref","first-page":"109138","DOI":"10.1016\/j.ymgme.2025.109138","article-title":"Newborn screening for metachromatic leukodystrophy: preparation of reagents and methodology for measurement of sulfatides and arylsulfatase A enzymatic activity in dried blood spots","volume":"145","author":"Shaff","year":"2025","journal-title":"Mol Genet Metab."},{"issue":"13","key":"2026083120025842700_r14","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMc2407165","article-title":"Newborn screening and presymptomatic treatment of metachromatic leukodystrophy","volume":"391","author":"Laugwitz","year":"2024","journal-title":"N Engl J Med."},{"issue":"7","key":"2026083120025842700_r15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcyt.2024.03.487","article-title":"Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States","volume":"26","author":"Adang","year":"2024","journal-title":"Cytotherapy."},{"key":"2026083120025842700_r16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejpn.2024.03.003","article-title":"Newborn screening in metachromatic leukodystrophy - European consensus-based recommendations on clinical management","volume":"49","author":"Laugwitz","year":"2024","journal-title":"Eur J Paediatr Neurol."},{"key":"2026083120025842700_r17","article-title":"Previously Nominated Conditions | HRSA","year":"2025"},{"issue":"5","key":"2026083120025842700_r18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7","volume":"32","author":"Eddy","year":"2012","journal-title":"Med Decis Making."},{"issue":"10322","key":"2026083120025842700_r19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet."},{"key":"2026083120025842700_r20","volume-title":"Gross Motor Function Measure (GMFM-66 and GMFM-88) User\u2019s Manual","author":"Russell","year":"2014","edition":"2nd ed"},{"issue":"2","key":"2026083120025842700_r21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1469-8749.2010.03821.x","article-title":"Development and reliability of a classification system for gross motor function in children with metachromatic leucodystrophy","volume":"53","author":"Kehrer","year":"2011","journal-title":"Dev Med Child Neurol."},{"issue":"1","key":"2026083120025842700_r22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13023-022-02189-w","article-title":"Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for metachromatic leukodystrophy: the European Metachromatic Leukodystrophy initiative (MLDi)","volume":"17","author":"Schoenmakers","year":"2022","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"2026083120025842700_r23","doi-asserted-by":"crossref","first-page":"108349","DOI":"10.1016\/j.ymgme.2024.108349","article-title":"Improving newborn screening test performance for metachromatic leukodystrophy: recommendation from a pre-pilot study that identified a late-infantile case for treatment","volume":"142","author":"Wu","year":"2024","journal-title":"Mol Genet Metab."},{"issue":"4","key":"2026083120025842700_r24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10048-020-00621-6","article-title":"Metachromatic leukodystrophy genotypes in The Netherlands reveal novel pathogenic ARSA variants in non-Caucasian patients","volume":"21","author":"Beerepoot","year":"2020","journal-title":"Neurogenetics."},{"issue":"1\u20132","key":"2026083120025842700_r25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The frequency of lysosomal storage diseases in The Netherlands","volume":"105","author":"Poorthuis","year":"1999","journal-title":"Hum Genet."},{"issue":"2","key":"2026083120025842700_r26","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.ymgme.2020.12.116","article-title":"Demographic and clinical characteristics of patients with metachromatic leukodystrophy in the United Kingdom: interim results from an observational real-world study","volume":"132","author":"Jones","year":"2021","journal-title":"Mol Genet Metab."},{"issue":"3","key":"2026083120025842700_r27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/ijns10030045","article-title":"Exploring the cost-effectiveness of newborn screening for metachromatic leukodystrophy (MLD) in the UK","volume":"10","author":"Bean","year":"2024","journal-title":"Int J Neonatal Screen."},{"issue":"12","key":"2026083120025842700_r28","doi-asserted-by":"crossref","first-page":"e240098","DOI":"10.57264\/cer-2024-0098","article-title":"Improving access to gene therapies: a holistic view of current challenges and future policy solutions in the United States","volume":"13","author":"Wagner","year":"2024","journal-title":"J Comp Eff Res."},{"issue":"2","key":"2026083120025842700_r29","doi-asserted-by":"crossref","first-page":"107769","DOI":"10.1016\/j.ymgme.2023.107769","article-title":"Cost-effectiveness framework by tandem mass spectrometry (TMS) for newborn screening of metachromatic leukodystrophy (MLD) in the United States (US)","volume":"141","author":"Bean","year":"2024","journal-title":"Mol Genet Metab."},{"issue":"5","key":"2026083120025842700_r30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/d41573-024-00056-w","article-title":"FDA approves gene therapy for metachromatic leukodystrophy, the tenth for a genetic disease and the priciest yet","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discov."},{"issue":"12","key":"2026083120025842700_r31","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/j.jval.2023.09.812","article-title":"EE547 The societal costs of metachromatic leukodystrophy (MLD) in the United States","volume":"26","author":"Bean","year":"2023","journal-title":"Value Health."},{"issue":"6","key":"2026083120025842700_r32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jval.2025.01.019","article-title":"Mapping the landscape of open source health economic models: a systematic database review and analysis: an ISPOR Special Interest Group report","volume":"28","author":"Henderson","year":"2025","journal-title":"Value Health."},{"issue":"12","key":"2026083120025842700_r33","doi-asserted-by":"crossref","first-page":"e2140998","DOI":"10.1001\/jamanetworkopen.2021.40998","article-title":"Expert evaluation of strategies to modernize newborn screening in the United States","volume":"4","author":"Bailey","year":"2021","journal-title":"JAMA Netw Open."},{"issue":"2","key":"2026083120025842700_r34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40258-025-01013-3","article-title":"Data-related and methodological challenges in assessing the cost-effectiveness of traditional and genomic newborn screening programs","volume":"24","author":"Lamsal","year":"2026","journal-title":"Appl Health Econ Health Policy."},{"issue":"4","key":"2026083120025842700_r35","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/0022146510386794","article-title":"Patients-in-waiting: living between sickness and health in the genomics era","volume":"51","author":"Timmermans","year":"2010","journal-title":"J Health Soc Behav."},{"issue":"1","key":"2026083120025842700_r36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0030-1253412","article-title":"Metachromatic leukodystrophy--an update","volume":"41","author":"Gieselmann","year":"2010","journal-title":"Neuropediatrics."},{"issue":"7","key":"2026083120025842700_r37","doi-asserted-by":"crossref","first-page":"e185031","DOI":"10.1001\/jamanetworkopen.2018.5031","article-title":"Association of diagnosis of leukodystrophy with race and ethnicity among pediatric and adolescent patients","volume":"1","author":"Bonkowsky","year":"2018","journal-title":"JAMA Netw Open."},{"issue":"1","key":"2026083120025842700_r38","doi-asserted-by":"crossref","first-page":"108436","DOI":"10.1016\/j.ymgme.2024.108436","article-title":"Higher precision, first tier newborn screening for metachromatic leukodystrophy using 16:1-OH-sulfatide","volume":"142","author":"Bekri","year":"2024","journal-title":"Mol Genet Metab."},{"issue":"3","key":"2026083120025842700_r39","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41436-020-01017-5","article-title":"Toward newborn screening of metachromatic leukodystrophy: results from analysis of over 27,000 newborn dried blood spots","volume":"23","author":"Hong","year":"2021","journal-title":"Genet Med."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2026-077357G\/1954020\/pediatrics.2026077357g.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2026-077357G\/1954020\/pediatrics.2026077357g.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:03:07Z","timestamp":1788220987000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/158\/Supplement%202\/e2026077357G\/208752\/Decision-Analysis-to-Inform-Screening-of-the-Young"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":39,"journal-issue":{"issue":"Supplement 2","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2026-077357g","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"e2026077357G"}}